



LJMU Research Online

Dehnavi, S, Sadeghi, M, Penson, P, Banach, M, Jamialahmadi, T and Sahebkar, A

The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis

<http://researchonline.ljmu.ac.uk/id/eprint/11712/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Dehnavi, S, Sadeghi, M, Penson, P, Banach, M, Jamialahmadi, T and Sahebkar, A (2019) The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis. Journal of Clinical Medicine, 8 (11). ISSN 2077-0383

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>



Review

The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis

Sajad Dehnavi ¹, Mahvash Sadeghi ², Peter E. Penson ³, Maciej Banach ^{4,5}, Tannaz Jamialahmadi ^{6,7} and Amirhossein Sahebkar ^{8,9,10,*}

¹ Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran

² Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran

³ School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK

⁴ Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz 93-338, Poland

⁵ Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz 93-338, Poland

⁶ Halal Research Center of IRI, FDA, Tehran, Iran

⁷ Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran

⁸ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

⁹ Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

¹⁰ School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9188617871, Iran

* Correspondence: sahebkar@mums.ac.ir; amir_saheb2000@yahoo.com, Tel.: +985-118-002-288; Fax: +985-118-002-287

Received: 23 September 2019; Accepted: 28 October 2019; Published: 2 November 2019

Abstract: Atherosclerosis is a progressive, inflammatory cardiovascular disorder characterized by the development of lipid-filled plaques within arteries. Endothelial cell dysfunction in the walls of blood vessels results in an increase in vascular permeability, alteration of the components of the extracellular matrix, and retention of LDL in the sub-endothelial space, thereby accelerating plaque formation. Epigenetic modification by SUMOylation can influence the surface interactions of target proteins and affect cellular functionality, thereby regulating multiple cellular processes. Small ubiquitin-like modifier (SUMO) can modulate NF κ B and other proteins such as p53, KLF, and ERK5, which have critical roles in atherogenesis. Furthermore, SUMO regulates leukocyte recruitment and cytokine release and the expression of adherence molecules. In this review, we discuss the regulation by SUMO and SUMOylation modifications of proteins and pathways involved in atherosclerosis.

Keywords: small ubiquitin-like modifier (SUMO); SUMOylation; atherosclerosis

1. Introduction

The development and rupture of atherosclerotic plaques is the most important cause of major clinical cardiovascular events including myocardial infarction and stroke, which were responsible for one-quarter of the deaths worldwide in 2010 [1–3]. Atherosclerosis is a chronic, inflammatory, slowly progressing disorder of the arterial wall, characterized by the accumulation of lipids in the walls of large and medium-sized arteries and infiltration of immune cells, leading to the development of atherosclerotic plaques [2,4]. Atherosclerosis can develop asymptotically for decades until rupture or erosion of the plaque occurs, resulting in intravascular thrombosis, ischemia, and necrosis [5].

Numerous studies have demonstrated that high circulating concentrations of low-density lipoproteins (LDL) and the cholesterol carried within this lipoprotein accelerate the formation of atherosclerotic plaques [6]. Dyslipidemia and an imbalance in the influx and efflux of cellular cholesterol leads to accumulation, oxidation, and finally deposition of LDL and LDL-like particles in the vascular wall and is associated with endothelial cell activation in sites prone to atherosclerotic lesions [7–10]. Endothelial cell dysfunction occurs commonly in regions of the vessel that experience turbulent blood-flow. Plaque formation is associated with increased vascular permeability, altered composition of the extracellular matrix, and retention of LDL in the sub-endothelial space [6]. Activated endothelial cells up-regulate the expression of cell adherence molecules and release chemokines, leading to the recruitment and infiltration of immune cells, especially circular monocytes and T-lymphocytes [6,7,11–13]. LDL particles that become trapped in the intima of the vessel are modified by lipase and protease enzymes and oxidized by myeloperoxidase, lipoxygenase, and reactive oxygen species. They are then taken up by monocytes via scavenger receptors and by resident macrophages in the arterial lumen. As cholesterol esters accumulate as droplets in macrophages, these cells become “foam cells” that are a hallmark of the early stages of plaques [4,6,11,14–16]. Oxidized LDL (oxLDL) is a potential damage-associated molecular pattern (DAMP) and induces an inflammatory response.

Foam cells secrete inflammatory cytokines (interleukins and TNF- α) and chemokines (for example, monocyte chemoattractant protein-1 or MCP-1), and these events lead to exacerbation of the local inflammatory response. As the disease progresses, smooth muscle cells migrate to the intima of the affected vessels and initiate the secretion of extracellular matrix components that result in the formation of a fibrotic cap. Symptomatic manifestations of atherosclerosis begin when the fibrotic cap impedes blood flow, leading to angina, myocardial infarction, and stroke [4,17].

Multiple risk factors and pathological stimulants are involved in the pathogenesis of atherosclerosis, including hemodynamic forces, classical cardiovascular risk factors (hyperlipidemia, hyperglycemia and psychologic stress), smoking, diet, environmental factors, and genetics [18,19]. Epigenetics is the study of heritable chromatin modifications that control gene expression by changing the accessibility of DNA or chromatin structure [3,20]. Epigenetic changes, including post-translational modification of nuclear proteins, are involved in the initiation and progression of atherosclerosis. These modifications are dynamic and reversible and are potential targets for anti-atherosclerotic drugs.

2. Small Ubiquitin-Like Modifier (SUMO) Proteins and the Process of SUMOylation

Post-translational modifications (PTMs) are covalent, enzymatically catalyzed, modifications of proteins that result in functional changes. To date, more than 200 types of PTMs have been described in eukaryotes and prokaryotes, including ubiquitination, SUMOylation, phosphorylation, glycosylation, acetylation, and methylation [21–25].

PTM by SUMOylation is a critical regulator of the molecular, cellular and systemic functions of proteins. Small ubiquitin-like modifier (SUMO) protein is a member of the ubiquitin-like (Ubl) family with a molecular weight of 10KDa and four isoforms (1, 2, 3, and 4) in humans [26–29]. SUMO1 and SUMO2 have 50% sequence identity, whereas SUMO2 and SUMO3 have 97% similarity. Types 1, 2, and 3 are expressed ubiquitously, but SUMO4 is only found in the kidney, lymph nodes, and spleen [29–33].

The binding of SUMO to the target substrate is similar to the ubiquitination process and occurs via three distinct steps. First, attachment of SUMO to the E1 activating enzyme (SAE1/SAE2) in an ATP-dependent reaction leads to its activation. Then, activated SUMO is transferred to Ubc9, which is a member of the family of conjugating enzymes known as E2. Finally, Ubc9 targets the SUMO resulting in binding to the specific substrate that is covalently attached to an E3 ligase (PIAS (protein inhibitor of activated STAT), RanBP2 (Ran-binding protein 2), Pc2 (polycomb protein 2)). SUMOylation is a dynamic and reversible process, and SUMO-specific peptidase enzymes (SEN1, 2, 3, 5, 6, 7) catalyze the deSUMOylation reaction that detaches the SUMO that bond to the lysine residue of target proteins [28,30,34–38] (Figure 1).




Figure 1. Schematic summary of the SUMOylation pathway. The precursor of small ubiquitin-like modifier (SUMO) is matured by a member of the sentrin-specific protease (SENPs) family. This form has a C-terminal di-glycine motif. SUMO is then activated by E1 enzyme, a heterodimer of Aos1 and Uba2. Activated SUMO is passed to the active site of E2 conjugation enzyme, Ubc9. Finally, SUMO is transferred with E3 ligase to the target protein. DeSUMOylation of the substrate is caused by SENP family proteases.

SUMOylation can alter protein conformation and influence the surface interactions of target proteins. SUMOylation affects cellular functionality and regulates various cellular processes including intracellular trafficking, subcellular localization, protein–protein interactions, cell cycle progression, DNA repair and replication, RNA metabolism, apoptosis, protein stability, and the activity of kinases [26,28,32,39–42].

3. Blood Flows and Atherosclerosis

The inner surface of blood vessels is lined by a monolayer of endothelial cells that are constantly exposed to flow-derived forces including frictional force (hemodynamic shear stress), stretch, and hydrostatic pressure [43–47]. In large arteries, atherosclerotic plaques predominantly occur in regions in which blood flow is slow or disturbed. This localization suggests that local blood flow patterns have a crucial role in the formation and progression of atherosclerotic plaques. It has been demonstrated that different flow-patterns can modulate the structure and function of endothelial cells (ECs) and regulate the activation of pro-inflammatory and pro-apoptotic genes in ECs [17,47–49].

Blood-flow patterns include steady laminar flow (s-flow) and disturbed flow (d-flow). S-flow stimulates ECs to secrete factors that are inhibitors of coagulation, leukocyte inflammation, and smooth muscle cell proliferation as well as promotion of ECs survival [43,50]. Based on the observation that atherosclerotic plaques are rare in regions exposed to s-flow, it seems that this pattern of flow is anti-atherogenic. On the other hand, d-flow induces inflammation, apoptosis, proliferation of ECs and limited vascular reactivity. Most atherosclerotic plaques are located in regions of the arteries exposed to d-flow, such as curved regions. Because d-flow is pro-atherogenic and s-flow is anti-atherogenic, an understanding of molecular signalling pathways which induces by

different types of flow and influences on ECs are critical. For example, long-term stable flow up-regulates athero-protective and antioxidant genes such as KLF2, eNOS. Conversely, d-flow induces apoptosis, pro-inflammatory genes, and results in hotspots of ECs with enhanced permeability and inflammation [51–54].

4. NF κ B is a Regulator of Inflammation in ECs and a SUMOylation Target

EC dysfunction leads to pathological inflammation, apoptosis and enhanced cell permeability. Atherogenesis occurs as a result of leukocyte recruitment. The release of cytokines and the expression of adherence molecules are regulated by NF κ B [28]. The NF κ B family is a group of five transcription factors: p65 (relA), relB, c-Rel, p100/p52, and p100/p52. In its inactive state, NF κ B is found in the cytoplasm bound to an inhibitor of κ B (I κ B). Activation of NF κ B occurs when I κ B kinase (I κ K) is stimulated by an inflammatory factor (such as cytokines or d-flow) I κ K phosphorylates I κ B and leads to its inactivation via ubiquitination tumorigenesis and inflammatory and cardiovascular disorders [55]. The resultant free NF κ B translocates to the nucleus and trans-activates pro-inflammatory genes including VCAM-1, E-selectin, IL-8, IL-1, TNF, and ICAM-1 [56].

SUMOylation has been shown to regulate NF κ B through a variety of mechanisms. Modification of the NF κ B precursor (p100) activates non-canonical signalling pathways [57]. I κ K is a complex of two kinases (I κ K1 or I κ K α and I κ K2 or I κ K β) with a subunit called “NF κ B essential modulator” (NEMO) or I κ K γ . NEMO has no catalytic activity but is essential for I κ K activation and I κ B phosphorylation. Deletion of NEMO prevents I κ K from efficiently phosphorylating IB and activating NF κ B signalling [30,58]. Gareus and colleagues have demonstrated that endothelium-specific depletion of NEMO or dominant-negative I κ B α inhibits the formation of atherosclerotic plaque. This observation demonstrates the crucial role of the NF κ B signalling pathway in the pathogenesis of atherosclerosis [59]. It has recently been reported that modification of I κ B α by SUMO1 inhibits its ubiquitination and destruction and down-regulates NF κ B activation. In contrast, Modification of I κ B α by SUMO2/3 has the opposite effect and leads to the detachment of I κ B α from NF κ B and activation of this pathway [28,33,60]. Furthermore, investigations by Miyamoto et al. have demonstrated that genotoxic stress-induced NEMO SUMOylation by SUMO1 results in up-regulation of I κ K-NF κ B. Interestingly, SENP2 deSUMOylating enzyme, which is a transcriptional target downstream of NF κ B, provides a negative feedback mechanism for NF κ B activation via NEMO deSUMOylation. Additionally, deSUMOylation of NEMO in K277 via SENP6 inhibits TLR-induced inflammation [27,61–64].

5. Other Targets of SUMOylation Involved in the Pathogenesis of Atherosclerosis.

5.1. MAPK-Activated Protein Kinase-2 (MK2)

MK2 is a pro-inflammatory kinase that increases NF κ B activity by blocking the nuclear retention of p38 and inhibiting phosphorylation of mitogen- and stress-activated protein kinase 1 (MSK1). It has been reported that MK2 depletion significantly inhibits TNF α -induced inflammatory responses in ECs and plaque formation in LDLR $^{-/-}$ mice with decreased expression of VCAM-1 and MCP-1. This observation demonstrates that activation of MK2 in ECs is a pro-atherogenic event. SUMOylation of MK2 K339 inhibits its kinase activity, prevents actin filament remodelling and TNF α -mediated ECs migration. While the exact role of SUMO modification of MK2 is unclear, it may be an important regulator of EC function [33,65,66].

5.2. ERK5

Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases that regulate various cellular functions such as proliferation, differentiation, survival, and apoptosis. The MAPK family includes four major subfamilies, of which ERK5 is one of the most important [43]. ERK5 (also called MAPK7) has pivotal roles in endothelial hemostasis and has a unique role in protection against atherosclerosis because it is both a kinase enzyme and a transcription co-activator. As with all MAPKs, ERK5 requires phosphorylation on Thr-X-Thr motif for activation and has a trans-

activation motif at its C-terminus that regulates anti-inflammatory genes [51,67,68]. EC-specific ERK5 knockout mice show accelerated apoptosis, inflammation, and atherosclerosis plaque formation [69].

Activation of ERK5 occurs in response to s-flow and induction of upstream MEK5 α . Once activated, the arginine-rich middle region binds to the PPAR γ 1hinge-helix and upregulates the transcription activity of peroxisome proliferator-activated receptor γ (PPAR γ). Direct association of ERK5 and PPAR γ leads to the release of SMRT1, a PPAR γ -corepressor that down-regulates PPAR γ transcriptional activity. ERK5-PPAR γ association mediated-SMRT1 release leads to inhibition of TNF-mediated NF κ B activation and consequently to inflammatory responses [70–72]. It has also been demonstrated that ERK5 activation increases the transcriptional activity of PPAR δ and leads to inhibition of heme oxygenase1-induced inflammatory response. Moreover, MEK5 α /ERK5 activation increases the transcriptional activity of myocyte enhancer factor-2 (MEF-2) which is a critical component of the transcriptional system that is required for the regulation of KLF expression and leads to reduced inflammation. The KLF family, especially KLF2 and KLF4, are targets of ERK5 and play an important role in vascular biology including the regulation of EC inflammation, vascular tone, and permeability [30,73,74].

Hyperglycemia, oxidative stress, and d-flow are inducers of ERK5 SUMOylation and lead to dysfunction and inflammation of ECs. Under normal conditions, ERK5 is not SUMOylated, and SENP2 protects ECs by continuously removing this pathologic modification (ERK5 SUMOylation). SENP2 knockdown leads to increased ERK5 SUMOylation which induces apoptosis and inflammation. It is noteworthy that d-flow affects ERK5 SUMOylation without altering the expression of SENP2 [66]. It has been shown that d-flow induces apoptosis and inflammation via upregulation of ROS production. ROS induces endogenous ERK5 SUMOylation at lysine 6 and 22, leading to inhibition of the transcriptional activity of ERK5 in ECs. This SUMOylation-mediated inhibition of ERK5 reduces the s-flow-mediated KLF2 promoter activity and consequently reduces the expression of KLF2 and eNOS in ECs.

Interestingly, SUMOylation-mediated negative regulation of ERK5 transcriptional activity is independent of the phosphorylation and kinase activity of ERK5. Similarly, the kinase activity of ERK5 is not influenced by ERK5 SUMOylation. It has been suggested that SUMOylation of ERK5 and kinase activity are regulated independently of its transcriptional activity [30,33,43].

5.3. P90 Ribosomal s6 Kinase (p90RSK)

P90RSK is a well-characterized serine/threonine kinase that is unique in having two different kinase functional domains, one at each end. This enzyme plays an important role in EC dysfunction in cardiovascular disorders induced by diabetes mellitus [69].

P90RSK specifically binds to the C-terminus of ERK5 and phosphorylates the S496 residue, leading to activation of ECs and vascular reactivity and consequently increased expression of VCAM-1 and decreased eNOS. Additionally, p90RSK can modulate ERK5 SUMOylation in a SENP2-dependent pathway. Activation of p90RSK via d-flow leads to SENP2-T368 phosphorylation and nuclear export, which causes a reduction of the deSUMOylating activity of SENP2 and increases SUMOylation of p53 and ERK5 in the nucleus. Consequently, up-regulation of apoptosis and inflammation occur [45,47,52] (Figure 2). Inhibition of the transactivation activity of ERK5 leads to reduced expression of anti-inflammatory genes and causes ECs dysfunction. ECs-specific p90RSK overexpression has been shown to initiate ECs dysfunction and plaque formation in mouse aorta, but this does not occur in dominant-negative (DN)-p90RSK mice. Furthermore, SENP2 depletion in DN-p90RSK mice changes the athero-protective phenotype [47].




Figure 2 Pro-atherogenic effects of d-flow on inflammation and apoptosis in the p90RSK-dependent pathway. In the steady-state (s-flow), SENP2 enzyme deSUMOylate p53, and ERK5, which are key regulators of inflammation and apoptosis in ECs. Activation of p90RSK, as a result of disturbed flow (d-flow) leads to SENP2 enzyme inhibition. p53 and ERK5 remain in the SUMOylated form, which exacerbates inflammatory conditions and promotes cell proliferation following a decrease in the rate of apoptosis.

6. KLF

The proliferation of vascular smooth muscle cell (VSMC) is promoted by cyclin-mediated cell cycle progression and is inhibited by CDK inhibitors. This process plays a pivotal role in the pathogenesis of a variety of disorders including atherosclerosis, hypertension, and vascular aneurysms [75]. KLF is a family of transcription factors all contain zinc fingers. One member of the family, KLF4 has a crucial role in promoting the formation of pluripotent stem cells and is emerging as an important player in tumorigenesis and inflammatory and cardiovascular disorders. It has recently been demonstrated that KLF regulates VSMC proliferation and differentiation by multiple mechanisms [76–78].

SUMOylation enables KLF4 to have a dual role in transcription regulation in response to environmental and cellular stimulants. Non-SUMOylated KLF4 is associated with p300 and acts as an activator of p21 transcription and a negative regulator of cell proliferation. In response to PDGF-BB challenge, Ubc9 promotes KLF4 SUMOylation. Consequently, co-repressors, including NCoR, HDAC2, and LSD2, are recruited to the p21 promoter. Inhibition of p21 expression leads to the proliferation of VSMCs [79,80].

Conversely, KLF family members, especially KLF2 and KLF4, are targets of ERK5 that play a key role in the regulation of inflammation in ECs and vascular tone and permeability [67,74]. Both KLF2 and KLF4 are highly expressed by ECs and induced by s-flow, but inhibited by d-flow and diabetic mediators such as AGEs and H₂O₂. These factors inhibit inflammation by competing with CBP/p300 cofactor for binding sites on NFκB. Down-regulation of NFκB transcription activity by KLF2/4 leads to attenuation of the expression of pro-inflammatory mediators such as cytokines, chemokines and adherence molecules. Moreover, induction of KLF2/4 expression leads to up-regulation of eNOS expression which has vasodilation, anti-inflammatory and anticoagulant effects. Erk5 activation leads to MEF2 transactivation and consequently down-regulates KLF2/4 [73,81–83].

7. Membrane-Associated Guanylate Kinase with Inverted Domain Structure-1 (MAGI-1)

Membrane-associated guanylate kinase with inverted domain structure-1 (MAGI-1) is a scaffold protein with six PSD95/DiscLarge/ZO-1 domains, one guanylate kinase domain, and two WW (rsp5)

domains that is widely expressed in a variety of tissues, although not in skeletal muscle. MAGI-1 is associated with adherence junctions and is required for cell–cell adhesion and maturation of VE cadherin–mediated adherence junctions. Recently, a genome wide-associated study (GWAS) showed an association between the MAGI-1 locus and the severity of a variety of chronic inflammatory disorders [52,84–88].

It has been demonstrated that MAGI-1 can simultaneously modulate EC activation and apoptosis induced by endoplasmic reticulum stress. These are crucial molecular events in atherogenesis and are regulated by MAGI-1-K931 SUMOylation. DeSUMOylation of MAGI-1-K931 is required for nuclear translocation of p90RSK. Consequently, nuclear p90RSK phosphorylates ERK5-S496 and SENP2-T368 and exacerbates cellular inflammation. Depletion of MAGI-1 significantly inhibits d-flow-induced atherogenesis [45–47,69].

8. p53

p53 tumor suppressor plays an important role in determining whether cells undergo apoptosis or cell cycle arrest in response to a variety of stresses. Elevated nuclear p53 and up-regulation of pro-apoptotic genes and cell-cycle regulators occurs as a cellular response to DNA damage or stress [89,90]. The role of p53 in atherosclerosis and the biology of flow-sensitive ECs is complex. In human atherosclerotic plaques, elevated p53 has been observed in ECs, suggesting that p53 promotes atherosclerosis. Studies on transgenic mice have shown that p53 overexpression leads to inflammation and dysfunction in ECs via down-regulation of the anti-atherogenic factor KLF2.

Interestingly, p53 overexpression does not exacerbate atherosclerosis in transgenic mice [91–93]. Another study demonstrated that p53 knockout increases susceptibility to atherosclerosis and decreases vascular cell turnover. These controversial results may reflect different roles of p53 in different cell-types including ECs, smooth muscle cells, and macrophages [94–97].

In cultured ECs, exposure to d-flow results in the export p53 from the nucleus to the cytoplasm. This process is regulated by PKC ζ -mediated p53 SUMOylation. This occurs because d-flow leads to PKC ζ activation via induction of reactive oxygen species (ROS) production; consequently, activation of the PKC ζ occurs by interaction of its C-terminal kinase domain with RING domain of PIAS γ . The RING domain includes the SUMO ligase catalytic site. PIAS γ -PKC ζ association may increase the enzymatic activity of PIAS γ by altering its tertiary structure. PIAS γ -PKC ζ association up-regulates p53 SUMOylation. SUMOylated p53 is then transported from the nucleus to the cytoplasm [98]. In the cytoplasm, p53 induces apoptosis via direct interaction with Bax and Bcl-2, preventing the anti-apoptotic function of Bax/Bcl-2 and leading to apoptosis of ECs [53,89,99].

It has also been demonstrated that SENPs have a role in the control of d-flow-induced SUMOylation of p53 and ERK5. Six isoforms of SENPs are found in humans, including SENP2. Knockout SENP2 mice experienced accelerated plaque formation and up-regulation of inflammation and apoptosis in ECs. It appears that this deletion leads to elevated p53 and ERK5 SUMOylation [45,100,101].

9. Adenosine Monophosphate-Activated Protein Kinase (AMPK)

AMPK is a stress-activated kinase that controls cellular responses to a variety of stresses through regulation of metabolism, protein synthesis, autophagy, and apoptosis. The enzyme is composed of three subunits, including a catalytic (α) and two regulatory (β , γ) subunits. In unstressed cells, AMPK is localized in the cytoplasm, and it translocates to the nucleus after activation. AMPK can inhibit endoplasmic reticulum stress by reducing ROS production and eNOS activation [102–104].

The role of AMPK in the regulation of inflammation in ECs and atherogenesis is isoform-dependent. The α 1 isoform is pro-inflammatory, and the α 2 is anti-inflammatory. Decreased atherosclerotic plaques formation has been reported in AMPK α 1^{-/-}/ApoE^{-/-} knockouts, whereas it is increased in AMPK α 2^{-/-}/LDLR^{-/-} [105]. Rubio et al. demonstrated that SUMO2 modification of AMPK α 2 activates this enzyme and protects it from being inactivated via ubiquitination. However, SUMOylation inhibits the activity of AMPK α 1 [106].

10. Liver Receptor Homolog-1 (LRH-1)

LRH-1 or NR5A2, also called fetoprotein transcription factor, is a member of the NR5A subfamily of nuclear receptors (NRs) that are highly expressed in the intestine and liver and that regulate diverse functions from the development of cholesterol to bile acid hemostasis [107]. The transcriptional activity of LRH-1 is governed by multiple factors, including ligand binding and PTMs, which together dictate the interaction of the receptor and transcriptional co-regulators [108–110]. These receptors are targeted by E3-SUMO ligase for SUMOylation at various lysine residues that affect their transcriptional activity. Modification of this receptor by SUMO1 has been demonstrated at lysine 224 located in hinge region of receptor. SUMOylation of human LRH-1 decreases its transcriptional activity through a mechanism that is not yet fully understood. It has been shown that SUMOylation resulted in sequestration the receptor with promyelocytic leukemia (PML) protein bodies. It has been suggested that that SUMO modification of LRH-1 leads to stable recruitment of transcriptional nuclear receptor corepressor-1 and histone deacetylase 3 (NCoR1/HDAC3) corepressor complex and association to G protein pathway suppressor 2 (GPS2) [111–114].

Recently, Stein et al. demonstrated that modification of lysine 289 of LRH-1 by SUMOylation plays a key role in the formation of atherosclerotic plaques. LRH-1 K289R mice (mutant lysine 289) experience reduced SUMOylation of LRH-1. Loss of SUMOylation in K289 is sufficient for cholesterol transport and protection of mice against atherosclerosis [108].

11. Conclusion

Several studies have shown that epigenetic modifications contribute to the initiation and progression of atherosclerosis. Among these modifications, SUMOylation and SUMO protein modifications play important roles in the pathogenesis of atherosclerosis. SUMOylation affects various proteins and pathways including NFκB, ERK, p53, p90RSK, ERK, KLF, MK2, MAGI-1, AMPK, and LRH-1 which are pivotal regulators of the function of ECs (Table 1). Thus, dysregulated SUMO contributes substantially to the development of atherosclerosis. The development of research tools to study SUMOylation and the increasing number of in vivo and in vitro studies in this area have expanded our understanding of the role of the SUMOylation in these pathways. The crucial role of SUMO and SUMOylation in the formation of atherosclerotic plaques presents a novel therapeutic target in the management of atherosclerosis. Further work is required to develop and evaluate therapeutic agents that modulate SUMOylation and that can be used in the prevention and management of atherosclerosis.

Table 1. Summary of factors that affected by SUMO modifications and are involved in atherosclerosis pathogenesis.

Protein	General characteristics and association with pathogenesis of atherosclerosis	Consequences of SUMO modifications	Ref
NFκB	A family of transcriptional factors localized in the cytoplasm in the inactive form that require stimulation by an inflammatory factor to enable nuclear localization and subsequent activation of pro-inflammatory genes involved in atherogenesis	Down-regulation of NFκB pathway by SUMO1 modification of IκBα Up-regulation of NFκB pathway by SUMO2/3 modification of IκBα	[28,56,57]
MK2	A pro-inflammatory kinase that increases NFκB activity	Inhibition of its kinase activity by K339 SUMOylation	[33,66,67]
ERK5	A family of serine/threonine kinases that regulates various cellular functions especially in endothelial hemostasis and is protective against atherosclerosis	D-flow-induced ERK5 SUMOylation and EC dysfunction	[43,51,67–69]
p90RSK	A serine/threonine kinase associated with EC dysfunction in diabetes mellitus-induced cardiovascular disorders	Phosphorylation and consequent inhibition of SENP2 deSUMOylating enzymes which blocks activation of ERK5 and p53 genes	[33,70]
KLF	A family of transcription factors that play an important role in inflammatory and cardiovascular disorders	SUMOylation of KLF4 leads to recruitment of co-repressors to the	[68,75,80,81]

	KLF4 is a member of this family which acts as a negative regulator of cell proliferation via p21 interaction in non-SUMOylated state	p21 promoter and increases the proliferation of VSMCs	
MAGI-1	A scaffold protein that is associated with adherence junctions and modulates crucial molecular events in atherogenesis including the activation of ECs and endoplasmic reticulum stress-induced apoptosis.	DeSUMOylation of MAGI-1-K931 is required for nuclear translocation of p90RSK	[52,87]
p53	An important tumor suppressor that plays a role in determining the fate of cell for apoptosis or cell cycle arrest in response to various stresses	SUMOylated p53 exports from nucleus to the cytoplasm and induces ECs apoptosis via direct interaction by pro-apoptotic proteins	[33,90,91,102,103]
AMPK	A stress-activated kinase that orchestrates cellular responses to different stresses	AMPK α 2 activation and protection from UQ destruction via SUMO2 modification AMPK α 1 inhibition via SUMOylation	[106–108,110]
LRH-1	A member of NR5A subfamily for nuclear receptors with various functions such as cholesterol and bile acid hemostasis	Association of K289 LRH-1 SUMOylation and atherosclerosis pathogenesis	[111,112]

Funding: This research received no external funding

Conflicts of Interest: Dr. Penson owns four shares in Astra Zeneca PLC and has received travel/speaker's fees from Amgen Inc. Dr. Banach has served as speakers bureau for Abbott/Mylan, Abbott Vascular, Actavis, Akcea, Amgen, Biofarm, KRKA, MSD, Sanofi-Aventis and Valeant; consultant to Abbott Vascular, Akcea, Amgen, Daichii Sankyo, Esperion, Lilly, MSD, Resverlogix, Sanofi-Aventis; and received grants from Sanofi and Valeant. Other authors have no competing interests to declare.

References

- Björkbacka, H.; Nilsson, J. Innate immunity in atherosclerosis. *J. Innate Immun.* **2010**, *2*, 305.
- Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* **2012**, *380*, 2095–2128.
- Nicorescu, I.; Dallinga, G.M.; de Winther, M.P.; Stroes, E.S.; Bahjat, M. Potential epigenetic therapeutics for atherosclerosis treatment. *Atherosclerosis* **2018**, *281*, 189–197.
- Hansson, G.K.; Hermansson, A. The immune system in atherosclerosis. *Nat. Immunol.* **2011**, *12*, 204.
- Gisterå, A.; Hansson, G.K. The immunology of atherosclerosis. *Nat. Rev. Nephrol.* **2017**, *13*, 368.
- Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. *Nature* **2011**, *473*, 317.
- Mestas, J.; Ley, K. Monocyte-endothelial cell interactions in the development of atherosclerosis. *Trends Cardiovasc. Med.* **2008**, *18*, 228–232.
- Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. *N. Engl. J. Med.* **2005**, *352*, 1685–1695.
- Skälén, K.; Gustafsson, M.; Rydberg, E.K.; Hultén, L.M.; Wiklund, O.; Innerarity, T.L.; Borén, J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. *Nature* **2002**, *417*, 750.
- Williams, K.J.; Tabas, I. The response-to-retention hypothesis of early atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* **1995**, *15*, 551–561.
- Libby, P.; Lichtman, A.H.; Hansson, G.K. Immune effector mechanisms implicated in atherosclerosis: From mice to humans. *Immunity* **2013**, *38*, 1092–1104.
- Nakashima, Y.; Raines, E.W.; Plump, A.S.; Breslow, J.L.; Ross, R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. *Arterioscler. Thromb. Vasc. Biol.* **1998**, *18*, 842–851.
- Cybulsky, M.I.; Gimbrone, M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science* **1991**, *251*, 788–791.
- Libby, P. Inflammation in atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 2045–2051.
- Pentikäinen, M.; Öörni, K.; Ala-Korpela, M.; Kovanen, P. Modified LDL—Trigger of atherosclerosis and inflammation in the arterial intima. *J. Intern. Med.* **2000**, *247*, 359–370.

16. Park, Y.M.; Febbraio, M.; Silverstein, R.L. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. *J. Clin. Investig.* **2009**, *119*, 136–145.
17. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. *Circulation* **2002**, *105*, 1135–1143.
18. Joehanes, R.; Just, A.C.; Marioni, R.E.; Pilling, L.C.; Reynolds, L.M.; Mandaviya, P.R.; Guan, W.; Xu, T.; Elks, C.E.; Aslibekyan, S. Epigenetic signatures of cigarette smoking. *Circ. Cardiovasc. Genet.* **2016**, *9*, 436–447.
19. Xu, S.; Pelisek, J.; Jin, Z.G. Atherosclerosis is an epigenetic disease. *Trends Endocrinol. Metab.* **2018**, *29*, 739–742.
20. Fraga, M.F.; Ballestar, E.; Paz, M.F.; Ropero, S.; Setien, F.; Ballestar, M.L.; Heine-Suñer, D.; Cigudosa, J.C.; Urioste, M.; Benitez, J. Epigenetic differences arise during the lifetime of monozygotic twins. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 10604–10609.
21. Becares, N.; Gage, M.C.; Pineda-Torra, I. Posttranslational modifications of lipid-activated nuclear receptors: Focus on metabolism. *Endocrinology* **2016**, *158*, 213–225.
22. Lu, C.-T.; Huang, K.-Y.; Su, M.-G.; Lee, T.-Y.; Bretana, N.A.; Chang, W.-C.; Chen, Y.-J.; Chen, Y.-J.; Huang, H.-D. DbPTM 3.0: An informative resource for investigating substrate site specificity and functional association of protein post-translational modifications. *Nucleic Acids Res.* **2012**, *41*, 295–305.
23. Khoury, G.A.; Baliban, R.C.; Floudas, C.A. Proteome-wide post-translational modification statistics: Frequency analysis and curation of the swiss-prot database. *Sci. Rep.* **2011**, *1*, 90.
24. Beltrao, P.; Bork, P.; Krogan, N.J.; van Noort, V. Evolution and functional cross-talk of protein post-translational modifications. *Mol. Syst. Biol.* **2013**, *9*, 714.
25. Apweiler, R.; Martin, M.J.; O'Donovan, C.; Magrane, M.; Alam-Faruque, Y.; Antunes, R.; Barrell, D.; Bely, B.; Bingley, M.; Binns, D. The universal protein resource (UniProt) in 2010. *Nucleic Acids Res.* **2010**, *38*, 142–148.
26. Adorasio, S.; Fierabracci, A.; Muscari, I.; Liberati, A.M.; Ayroldi, E.; Migliorati, G.; Thuy, T.T.; Riccardi, C.; Delfino, D.V. SUMO proteins: Guardians of immune system. *J. Autoimmun.* **2017**, *84*, 21–28.
27. Liu, X.; Wang, Q.; Chen, W.; Wang, C. Dynamic regulation of innate immunity by ubiquitin and ubiquitin-like proteins. *Cytokine Growth Factor Rev.* **2013**, *24*, 559–570.
28. Chang, E.; Abe, J. Kinase-SUMO networks in diabetes-mediated cardiovascular disease. *Metab. Clin. Exp.* **2016**, *65*, 623–33.
29. Guo, B.; Yang, S.-H.; Witty, J.; Sharrocks, A. *Signalling Pathways and the Regulation of SUMO Modification*; Portland Press Limited: London, UK, 2007.
30. Le, N.T.; Corsetti, J.P.; Dehoff-Sparks, J.L.; Sparks, C.E.; Fujiwara, K.; Abe, J. Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation. *Int. J. Inflamm.* **2012**, *2012*, 678190.
31. Gill, G. SUMO and ubiquitin in the nucleus: Different functions, similar mechanisms? *Genes Dev.* **2004**, *18*, 2046–2059.
32. Geiss-Friedlander, R.; Melchior, F. Concepts in sumoylation: A decade on. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 947.
33. Le, N.-T.; Sandhu, U.G.; Quintana-Quezada, R.A.; Hoang, N.M.; Fujiwara, K.; Abe, J.-I. Flow signaling and atherosclerosis. *Cell. Mol. Life Sci.* **2017**, *74*, 1835–1858.
34. Dehnavi, S.; Sadeghi, M.; Johnston, T.P.; Barreto, G.; Shohan, M.; Sahebkar, A. The role of protein SUMOylation in rheumatoid arthritis. *J. Autoimmun.* **2019**, *102*, 1–7.
35. Hickey, C.M.; Wilson, N.R.; Hochstrasser, M. Function and regulation of SUMO proteases. *Nat. Rev. Mol. Cell Biol.* **2012**, *13*, 755–766.
36. Schwertman, P.; Bekker-Jensen, S.; Mailand, N. Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 379–394.
37. Gao, C.; Huang, W.; Kanasaki, K.; Xu, Y. The role of ubiquitination and sumoylation in diabetic nephropathy. *Biomed. Res. Int.* **2014**, *2014*, 160692.
38. Yeh, E.T. SUMOylation and De-SUMOylation: Wrestling with life's processes. *J. Biol. Chem.* **2009**, *284*, 8223–8237.
39. Yang, L.; Lin, C.; Liu, W.; Zhang, J.; Ohgi, K.A.; Grinstein, J.D.; Dorrestein, P.C.; Rosenfeld, M.G. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. *Cell* **2011**, *147*, 773–788.

40. Dutchak, P.A.; Katafuchi, T.; Bookout, A.L.; Choi, J.H.; Ruth, T.Y.; Mangelsdorf, D.J.; Kliewer, S.A. Fibroblast growth factor-21 regulates PPAR γ activity and the antidiabetic actions of thiazolidinediones. *Cell* **2012**, *148*, 556–567.
41. Rosonina, E.; Akhter, A.; Dou, Y.; Babu, J.; Sri Theivakadacham, V.S. Regulation of transcription factors by sumoylation. *Transcription*. **2017**, *8*, 220–231.
42. Hilgarth, R.S.; Murphy, L.A.; Skaggs, H.S.; Wilkerson, D.C.; Xing, H.; Sarge, K.D. Regulation and function of SUMO modification. *J. Biol. Chem.* **2004**, *279*, 53899–53902.
43. Abe, J.-I.; Le, N.-T.; Heo, K.-S. Role for SUMOylation in disturbed flow-induced atherosclerotic plaque formation. *Biomed. Eng. Lett.* **2015**, *5*, 162–171.
44. Davies, P.F.; Civelek, M.; Fang, Y.; Guerraty, M.A.; Passerini, A.G. Seminars in Thrombosis and Hemostasis. In *Endothelial Heterogeneity Associated with Regional Athero-Susceptibility and Adaptation to Disturbed Blood Flow in Vivo*; Thieme Medical Publishers: New York, NY, USA, 2010; pp. 265–275.
45. Heo, K.-S.; Chang, E.; Le, N.-T.; Cushman, H.; Yeh, E.T.; Fujiwara, K.; Abe, J.-I. De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow—Induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. *Circ. Res.* **2013**, *112*, 911–923.
46. Heo, K.-S.; Fujiwara, K.; Abe, J.-I. Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. *Circ. J.* **2011**, *75*, 2722–2730.
47. Heo, K.-S.; Le, N.-T.; Cushman, H.J.; Giancursio, C.J.; Chang, E.; Woo, C.-H.; Sullivan, M.A.; Taunton, J.; Yeh, E.T.; Fujiwara, K. Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. *J. Clin. Investig.* **2015**, *125*, 1299–1310.
48. Urbich, C.; Stein, M.; Reisinger, K.; Kaufmann, R.; Dimmeler, S.; Gille, J. Fluid shear stress-induced transcriptional activation of the vascular endothelial growth factor receptor-2 gene requires Sp1-dependent DNA binding. *FEBS Lett.* **2003**, *535*, 87–93.
49. Huddleson, J.P.; Srinivasan, S.; Ahmad, N.; Lingrel, J.B. Fluid shear stress induces endothelial KLF2 gene expression through a defined promoter region. *Biol. Chem.* **2004**, *385*, 723–729.
50. Reinhart-King, C.A.; Fujiwara, K.; Berk, B.C. Physiologic stress-mediated signaling in the endothelium. *Methods Enzymol.* **2008**, *443*, 25–44.
51. Abe, J.-I.; Berk, B.C. Novel mechanisms of endothelial mechanotransduction. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 2378–2386.
52. Abe, J.-I.; Ko, K.A.; Kotla, S.; Wang, Y.; Paez-Mayorga, J.; Shin, I.J.; Imanishi, M.; Vu, H.T.; Tao, Y.; Leiva-Juarez, M.M. MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis. *JCI Insight* **2019**, *4*, e125570.
53. Nigro, P.; Abe, J.; Berk, B.C. Flow shear stress and atherosclerosis: a matter of site specificity. *Antioxid. Redox. Signal.* **2011**, *15*, 1405–1414.
54. Ni, C.-W.; Qiu, H.; Rezvan, A.; Kwon, K.; Nam, D.; Son, D.J.; Visvader, J.E.; Jo, H. Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. *Blood* **2010**, *116*, 66–73.
55. Brown, K.; Gerstberger, S.; Carlson, L.; Franzoso, G.; Siebenlist, U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. *Science* **1995**, *267*, 1485–1488.
56. Xiao, L.; Liu, Y.; Wang, N. New paradigms in inflammatory signaling in vascular endothelial cells. *Am. J. Physiol. Heart Circ. Physiol.* **2014**, *306*, 317–325.
57. Vatsyayan, J.; Qing, G.; Xiao, G.; Hu, J. SUMO1 modification of NF-kappaB2/p100 is essential for stimuli-induced p100 phosphorylation and processing. *EMBO Rep.* **2008**, *9*, 885–890.
58. Schmidt-Supprian, M.; Bloch, W.; Courtois, G.; Addicks, K.; Israël, A.; Rajewsky, K.; Pasparakis, M. NEMO/IKK γ -deficient mice model incontinentia pigmenti. *Mol. Cell* **2000**, *5*, 981–992.
59. Gareus, R.; Kotsaki, E.; Xanthoulea, S.; van der Made, I.; Gijbels, M.J.; Kardakaris, R.; Polykratis, A.; Kollias, G.; de Winther, M.P.; Pasparakis, M. Endothelial cell-specific NF- κ B inhibition protects mice from atherosclerosis. *Cell Metab.* **2008**, *8*, 372–383.
60. Desterro, J.M.; Rodriguez, M.S.; Hay, R.T. SUMO-1 modification of I κ B α inhibits NF- κ B activation. *Mol. Cell* **1998**, *2*, 233–239.
61. Lee, M.H.; Mabb, A.M.; Gill, G.B.; Yeh, E.T.; Miyamoto, S. NF- κ B induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. *Mol. Cell* **2011**, *43*, 180–191.
62. Yang, Y.; Xia, F.; Hermance, N.; Mabb, A.; Simonson, S.; Morrissey, S.; Gandhi, P.; Munson, M.; Miyamoto, S.; Kelliher, M.A. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF- κ B and p38

- mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. *Mol. Cell. Biol.* **2011**, *31*, 2774–2786.
63. Miyamoto, S. Nuclear initiated NF- κ B signaling: NEMO and ATM take center stage. *Cell Res.* **2011**, *21*, 116.
64. Wuerzberger-Davis, S.; Nakamura, Y.; Seufzer, B.; Miyamoto, S. NF- κ B activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. *Oncogene* **2007**, *26*, 641.
65. Jagavelu, K.; Tietge, U.J.; Gaestel, M.; Drexler, H.; Schieffer, B.; Bavendiek, U. Systemic Deficiency of the MAP Kinase—Activated Protein Kinase 2 Reduces Atherosclerosis in Hypercholesterolemic Mice. *Circ. Res.* **2007**, *101*, 1104–1112.
66. Chang, E.; Heo, K.-S.; Woo, C.-H.; Lee, H.; Le, N.-T.; Thomas, T.N.; Fujiwara, K.; Abe, J.-I. MK2 SUMOylation regulates actin filament remodeling and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation. *Blood* **2011**, *117*, 2527–2537.
67. Akaike, M.; Che, W.; Marmarosh, N.-L.; Ohta, S.; Osawa, M.; Ding, B.; Berk, B.C.; Yan, C.; Abe, J.-I. The hinge-helix 1 region of peroxisome proliferator-activated receptor γ 1 (PPAR γ 1) mediates interaction with extracellular signal-regulated kinase 5 and PPAR γ 1 transcriptional activation: Involvement in flow-induced PPAR γ activation in endothelial cells. *Mol. Cell. Biol.* **2004**, *24*, 8691–8704.
68. Kasler, H.G.; Victoria, J.; Duramad, O.; Winoto, A. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. *Mol. Cell. Biol.* **2000**, *20*, 8382–8389.
69. Le, N.-T.; Heo, K.-S.; Takei, Y.; Lee, H.; Woo, C.-H.; Chang, E.; McClain, C.; Hurley, C.; Wang, X.; Li, F. A crucial role for p90RSK-mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and atherosclerosis. *Circulation* **2013**, *127*, 486–499.
70. Woo, C.-H.; Shishido, T.; McClain, C.; Lim, J.H.; Li, J.-D.; Yang, J.; Yan, C.; Abe, J.-I. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress—Induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. *Circ. Res.* **2008**, *102*, 538–545.
71. Lee, C.-H.; Chawla, A.; Urbiztondo, N.; Liao, D.; Boisvert, W.A.; Evans, R.M. Transcriptional repression of atherogenic inflammation: Modulation by PPAR δ . *Science* **2003**, *302*, 453–457.
72. Barish, G.D.; Ruth, T.Y.; Karunasiri, M.S.; Becerra, D.; Kim, J.; Tseng, T.W.; Tai, L.-J.; LeBlanc, M.; Diehl, C.; Cerchietti, L. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. *Cell Metab.* **2012**, *15*, 554–562.
73. Ohnesorge, N.; Viemann, D.; Schmidt, N.; Czymai, T.; Spiering, D.; Schmolke, M.; Ludwig, S.; Roth, J.; Goebeler, M.; Schmidt, M. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Krüppel-like factor 4 (KLF4). *J. Biol. Chem.* **2010**, *285*, 26199–26210.
74. Parmar, K.M.; Larman, H.B.; Dai, G.; Zhang, Y.; Wang, E.T.; Moorthy, S.N.; Kratz, J.R.; Lin, Z.; Jain, M.K.; Gimbrone, M.A. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. *J. Clin. Investig.* **2006**, *116*, 49–58.
75. Zhou, A.-X.; Wang, X.; Lin, C.S.; Han, J.; Yong, J.; Nadolski, M.J.; Borén, J.; Kaufman, R.J.; Tabas, I. C/EBP-homologous protein (CHOP) in vascular smooth muscle cells regulates their proliferation in aortic explants and atherosclerotic lesions. *Circ. Res.* **2015**, *116*, 1736–1743.
76. Nie, C.-J.; Hui, L.Y.; Zhang, X.-H.; Wang, Z.-P.; Jiang, W.; Zhang, Y.; Yin, W.-N.; Zhang, Y.; Shi, H.-J.; Liu, Y. SUMOylation of KLF4 acts as a switch in transcriptional programs that control VSMC proliferation. *Exp. Cell Res.* **2016**, *342*, 20–31.
77. Aksoy, I.; Giudice, V.; Delahaye, E.; Wianny, F.; Aubry, M.; Mure, M.; Chen, J.; Jauch, R.; Bogu, G.K.; Nolden, T. Klf4 and Klf5 differentially inhibit mesoderm and endoderm differentiation in embryonic stem cells. *Nat. Commun.* **2014**, *5*, 3719.
78. Shankman, L.S.; Gomez, D.; Cherepanova, O.A.; Salmon, M.; Alencar, G.F.; Haskins, R.M.; Swiatlowska, P.; Newman, A.A.; Greene, E.S.; Straub, A.C. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. *Nat. Med.* **2015**, *21*, 628.
79. Hong, H.; Takahashi, K.; Ichisaka, T.; Aoi, T.; Kanagawa, O.; Nakagawa, M.; Okita, K.; Yamanaka, S. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. *Nature* **2009**, *460*, 1132.
80. Li, H.; Niu, H.; Peng, Y.; Wang, J.; He, P. Ubc9 promotes invasion and metastasis of lung cancer cells. *Oncol. Rep.* **2013**, *29*, 1588–1594.
81. SenBanerjee, S.; Lin, Z.; Atkins, G.B.; Greif, D.M.; Rao, R.M.; Kumar, A.; Feinberg, M.W.; Chen, Z.; Simon, D.I.; Lusinskas, F.W. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. *J. Exp. Med.* **2004**, *199*, 1305–1315.

82. Sen-Banerjee, S.; Mir, S.; Lin, Z.; Hamik, A.; Atkins, G.B.; Das, H.; Banerjee, P.; Kumar, A.; Jain, M.K. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. *Circ. Hagerstown* **2005**, *112*, 720–726.
83. Lin, Z.; Natesan, V.; Shi, H.; Dong, F.; Kawanami, D.; Mahabeleshwar, G.H.; Atkins, G.B.; Nayak, L.; Cui, Y.; Finigan, J.H. Kruppel-like factor 2 regulates endothelial barrier function. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 1952–1959.
84. Arnau-Soler, A.; Adams, M.J.; Hayward, C.; Thomson, P.A. Genome-wide interaction study of a proxy for stress-sensitivity and its prediction of major depressive disorder. *PLoS ONE* **2018**, *13*, e0209160.
85. Alonso, A.; Domenech, E.; Julia, A.; Panes, J.; Garcia-Sanchez, V.; Mateu, P.N.; Gutierrez, A.; Gomollon, F.; Mendoza, J.L.; Garcia-Planella, E.; et al. Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study. *Gastroenterology* **2015**, *148*, 794–805.
86. Julia, A.; Pinto, J.A.; Gratacos, J.; Queiro, R.; Ferrandiz, C.; Fonseca, E.; Montilla, C.; Torre-Alonso, J.C.; Puig, L.; Perez Venegas, J.J.; et al. A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. *Ann. Rheum. Dis.* **2015**, *74*, 1875–1881.
87. Camilleri, M.; Carlson, P.; Valentin, N.; Acosta, A.; O'Neill, J.; Eckert, D.; Dyer, R.; Na, J.; Klee, E.W.; Murray, J.A. Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2016**, *311*, 365–376.
88. Feng, X.; Jia, S.; Martin, T.A.; Jiang, W.G. Regulation and involvement in cancer and pathological conditions of MAGI1, a tight junction protein. *Anticancer Res.* **2014**, *34*, 3251–3256.
89. Mihara, M.; Erster, S.; Zaika, A.; Petrenko, O.; Chittenden, T.; Pancoska, P.; Moll, U.M. p53 has a direct apoptogenic role at the mitochondria. *Mol. Cell* **2003**, *11*, 577–590.
90. Teodoro, J.G.; Parker, A.E.; Zhu, X.; Green, M.R. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. *Science* **2006**, *313*, 968–971.
91. Takabe, W.; Alberts-Grill, N.; Jo, H. Disturbed flow: p53 SUMOylation in the turnover of endothelial cells. *J. Cell Biol.* **2011**, *193*, 805–807.
92. Sanz-González, S.M.; Barquín, L.; García-Cao, I.; Roque, M.; González, J.M.; Fuster, J.J.; Castells, M.T.; Flores, J.M.; Serrano, M.; Andrés, V. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. *Cardiovasc. Res.* **2007**, *75*, 803–812.
93. Kumar, A.; Kim, C.-S.; Hoffman, T.A.; Naqvi, A.; DeRicco, J.; Jung, S.-B.; Lin, Z.; Jain, M.K.; Irani, K. p53 impairs endothelial function by transcriptionally repressing Kruppel-Like Factor 2. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 133–141.
94. Guevara, N.V.; Kim, H.-S.; Antonova, E.I.; Chan, L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. *Nat. Med.* **1999**, *5*, 335.
95. Mercer, J.; Mahmoudi, M.; Bennett, M. DNA damage, p53, apoptosis and vascular disease. *Mutat. Res. Fundam. Mol. Mech. Mutagenesis* **2007**, *621*, 75–86.
96. Mercer, J.; Bennett, M. The role of p53 in atherosclerosis. *Cell Cycle Georget. Tex.* **2006**, *5*, 1907–1909.
97. Khanna, A.K. Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis. *J. Biomed. Sci.* **2009**, *16*, 66.
98. Santiago, A.; Li, D.; Zhao, L.Y.; Godsey, A.; Liao, D. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. *Mol. Biol. Cell* **2013**, *24*, 2739–2752.
99. Heo, K.-S.; Lee, H.; Nigro, P.; Thomas, T.; Le, N.-T.; Chang, E.; McClain, C.; Reinhart-King, C.A.; King, M.R.; Berk, B.C. PKC ζ mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. *J. Cell Biol.* **2011**, *193*, 867–884.
100. Johnson, E.S. Protein modification by SUMO. *Annu. Rev. Biochem.* **2004**, *73*, 355–382.
101. Nigro, P.; Abe, J.-I.; Woo, C.-H.; Satoh, K.; McClain, C.; O'Dell, M.R.; Lee, H.; Lim, J.-H.; Li, J.-D.; Heo, K.-S. PKC ζ decreases eNOS protein stability via inhibitory phosphorylation of ERK5. *Blood* **2010**, *116*, 1971–1979.
102. Zaha, V.G.; Young, L.H. AMP-activated protein kinase regulation and biological actions in the heart. *Circ. Res.* **2012**, *111*, 800–814.
103. Zhang, Y.; Lee, T.-S.; Kolb, E.M.; Sun, K.; Lu, X.; Sladek, F.M.; Kassab, G.S.; Garland, T.; Shyy, J.Y.-J. AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. *Arterioscler. Thromb. Vasc. Biol.* **2006**, *26*, 1281–1287.

104. Dong, Y.; Zhang, M.; Liang, B.; Xie, Z.; Zhao, Z.; Asfa, S.; Choi, H.C.; Zou, M.-H. Reduction of AMP-activated protein kinase alpha 2 increases endoplasmic reticulum stress and atherosclerosis in vivo. *Circulation* **2010**, *121*, 792.
105. Wang, Q.; Zhang, M.; Liang, B.; Shirwany, N.; Zhu, Y.; Zou, M.-H. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: The role of uncoupling protein 2. *PLoS ONE* **2011**, *6*, e25436.
106. Rubio, T.; Vernia, S.; Sanz, P. Sumoylation of AMPK β 2 subunit enhances AMP-activated protein kinase activity. *Mol. Biol. Cell* **2013**, *24*, 1801–1811.
107. Fayard, E.; Auwerx, J.; Schoonjans, K. LRH-1: An orphan nuclear receptor involved in development, metabolism and steroidogenesis. *Trends Cell Biol.* **2004**, *14*, 250–260.
108. Stein, S.; Oosterveer, M.H.; Matak, C.; Xu, P.; Lemos, V.; Havinga, R.; Dittner, C.; Ryu, D.; Menzies, K.J.; Wang, X. SUMOylation-dependent LRH-1/PROX1 interaction promotes atherosclerosis by decreasing hepatic reverse cholesterol transport. *Cell Metab.* **2014**, *20*, 603–613.
109. Lee, Y.-K.; Moore, D.D. Liver receptor homolog-1, an emerging metabolic modulator. *Front. Biosci.* **2008**, *13*, 5950–5958.
110. Fernandez-Marcos, P.J.; Auwerx, J.; Schoonjans, K. Emerging actions of the nuclear receptor LRH-1 in the gut. *Biochim. Biophys. Acta Mol. Basis Dis.* **2011**, *1812*, 947–955.
111. Chalkiadaki, A.; Talianidis, I. SUMO-dependent compartmentalization in promyelocytic leukemia protein nuclear bodies prevents the access of LRH-1 to chromatin. *Mol. Cell. Biol.* **2005**, *25*, 5095–5105.
112. Lee, M.B.; Lebedeva, L.A.; Suzawa, M.; Wadekar, S.A.; Desclozeaux, M.; Ingraham, H.A. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. *Mol. Cell. Biol.* **2005**, *25*, 1879–1890.
113. Talamillo, A.; Herboso, L.; Pirone, L.; Pérez, C.; Gonzalez, M.; Sánchez, J.; Mayor, U.; Lopitz-Otsoa, F.; Rodriguez, M.S.; Sutherland, J.D. Scavenger receptors mediate the role of SUMO and Ftz-f1 in *Drosophila* steroidogenesis. *PLoS Genet.* **2013**, *9*, e1003473.
114. Ward, J.D.; Bojanala, N.; Bernal, T.; Ashrafi, K.; Asahina, M.; Yamamoto, K.R. Sumoylated NHR-25/NR5A regulates cell fate during *C. elegans* vulval development. *PLoS Genet.* **2013**, *9*, e1003992.

